PDCD1 and neoplasm: Th17-IL-17 pathway plays a key role in prostate cancer progression, targeting IL17 pathway could prevent micro-invasive prostate cancer in a mouse model [29], and blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer [30].